GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Scaled Net Operating Assets

Satellos Bioscience (TSX:MSCL) Scaled Net Operating Assets : -0.09 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Satellos Bioscience's operating assets for the quarter that ended in Sep. 2024 was C$0.79 Mil. Satellos Bioscience's operating liabilities for the quarter that ended in Sep. 2024 was C$3.62 Mil. Satellos Bioscience's Total Assets for the quarter that ended in Jun. 2024 was C$33.19 Mil. Therefore, Satellos Bioscience's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was -0.09.


Satellos Bioscience Scaled Net Operating Assets Historical Data

The historical data trend for Satellos Bioscience's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Scaled Net Operating Assets Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
0.17 4.97 0.12 0.18

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.02 0.03 0.04 -0.09

Competitive Comparison of Satellos Bioscience's Scaled Net Operating Assets

For the Biotechnology subindustry, Satellos Bioscience's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Satellos Bioscience's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satellos Bioscience's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Satellos Bioscience's Scaled Net Operating Assets falls into.



Satellos Bioscience Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Satellos Bioscience's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(4.711-3.624)/6.199
=0.18

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=44.298 - 39.587
=4.711

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3.624 - 0 - 0
=3.624

Satellos Bioscience's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(0.787-3.622)/33.193
=-0.09

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=24.209 - 23.422
=0.787

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=3.622 - 0 - 0
=3.622

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Satellos Bioscience Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Satellos Bioscience Business Description

Traded in Other Exchanges
Address
200 Bay Street, Suite 2800, Royal Bank Plaza, South Tower, Toronto, ON, CAN, M5J 2J1
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience Headlines

No Headlines